FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312463852> ?p ?o ?g. }

• W4312463852 abstract "Background and importance In 2019, the National Health System (NHS) approved funding for the indication of pre-exposure prophylaxis (PreP) as an strategy to prevent human immunodeficiency virus (HIV) infection in high-risk populations. The hospital pharmacy (HP), together with the Sexually Transmitted Infection (STI) centre, has created an interdisciplinary circuit where these individuals are closely monitored. Aim and objectives To characterise the user population of the HIV PrEP programme and assess the adequacy of the circuit, as well as the impact of the SARS-CoV-2 pandemic. Material and methods Retrospective observational study of the PrEP programme from November 2019 to April 2021 carried out in the provincial STI treatment centre and the HP. The following were assessed: compliance with inclusion criteria, adherence to treatment and causes of discontinuation, toxicity, acquisition of STIs and interactions. Also variations during confinement and degree of involvement by COVID. Results 169 males, aged 39.6±10.0 (range 19–64) years, all met at least one inclusion criterion in the last year: 75.7% (n=128) men who have sex with men (MSM) with more than 10 different sexual partners, 71.6% (n=121) MSM anal sex without condoms, 17.1% (n=29) MSM drug use, 10.7% (n=18) MSM with multiple PreP, 74.0% (n=125) MSM with at least one STI and one engaged in prostitution. 30 clients discontinued medication: 33.3% (n=10) stopped risky practices, 20.0% (n=6) digestive toxicity (main adverse effect), 3.3% (n=1) poor adherence, 16.7% (n=5) client choice and 26.7% (n=8) drop out of follow-up. Mean adherence was 94.5±11.4. No patients acquired HIV during treatment, but other STIs were found (several users reported reduced of condom use): 36.7% (n=11) Treponema pallidum , 56.7% (n=17) Chlamydia trachomatis , 63.3% (n=19) Neisseria gonorrhoeae and 36.7% (n=11) Mycoplasma genitalum . This was a young population that does a lot of physical exercise and after the clinical interview it was discovered they were abusing protein shakes and anabolic steroids, therefore they were warned about it. During the confinement, 41 users were in treatment. Of the 37 who continued, 4 suffered from COVID. Conclusion and relevance The programme meets the requirements of the NHS, with high adherence to treatment and a good safety profile. Patients continued with PreP during confinement and there was a significant number affected by COVID. Clinical pharmaceutical follow-up has allowed preventive and corrective interventions, but more emphasis should be placed on the use of condoms and avoiding anabolic steroids given the possible renal repercussions. Conflict of interest No conflict of interest" @default.
• W4312463852 created "2023-01-04" @default.
• W4312463852 creator A5001921230 @default.
• W4312463852 creator A5007756919 @default.
• W4312463852 creator A5036704272 @default.
• W4312463852 creator A5037586725 @default.
• W4312463852 creator A5055698039 @default.
• W4312463852 creator A5058883224 @default.
• W4312463852 creator A5060805960 @default.
• W4312463852 creator A5068812183 @default.
• W4312463852 creator A5085278024 @default.
• W4312463852 date "2022-03-01" @default.
• W4312463852 modified "2023-10-15" @default.
• W4312463852 title "4CPS-242 Human immunodeficiency virus pre-exposure prophylaxis: analysis, follow-up and pandemic effect" @default.
• W4312463852 doi "https://doi.org/10.1136/ejhpharm-2022-eahp.409" @default.
• W4312463852 hasPublicationYear "2022" @default.
• W4312463852 type Work @default.
• W4312463852 citedByCount "0" @default.
• W4312463852 crossrefType "proceedings-article" @default.
• W4312463852 hasAuthorship W4312463852A5001921230 @default.
• W4312463852 hasAuthorship W4312463852A5007756919 @default.
• W4312463852 hasAuthorship W4312463852A5036704272 @default.
• W4312463852 hasAuthorship W4312463852A5037586725 @default.
• W4312463852 hasAuthorship W4312463852A5055698039 @default.
• W4312463852 hasAuthorship W4312463852A5058883224 @default.
• W4312463852 hasAuthorship W4312463852A5060805960 @default.
• W4312463852 hasAuthorship W4312463852A5068812183 @default.
• W4312463852 hasAuthorship W4312463852A5085278024 @default.
• W4312463852 hasBestOaLocation W43124638521 @default.
• W4312463852 hasConcept C104863432 @default.
• W4312463852 hasConcept C126322002 @default.
• W4312463852 hasConcept C197934379 @default.
• W4312463852 hasConcept C23131810 @default.
• W4312463852 hasConcept C2776939746 @default.
• W4312463852 hasConcept C2776983459 @default.
• W4312463852 hasConcept C2778715236 @default.
• W4312463852 hasConcept C2779134260 @default.
• W4312463852 hasConcept C2779496540 @default.
• W4312463852 hasConcept C2908647359 @default.
• W4312463852 hasConcept C3008058167 @default.
• W4312463852 hasConcept C3013748606 @default.
• W4312463852 hasConcept C512399662 @default.
• W4312463852 hasConcept C524204448 @default.
• W4312463852 hasConcept C71924100 @default.
• W4312463852 hasConcept C89623803 @default.
• W4312463852 hasConcept C99454951 @default.
• W4312463852 hasConceptScore W4312463852C104863432 @default.
• W4312463852 hasConceptScore W4312463852C126322002 @default.
• W4312463852 hasConceptScore W4312463852C197934379 @default.
• W4312463852 hasConceptScore W4312463852C23131810 @default.
• W4312463852 hasConceptScore W4312463852C2776939746 @default.
• W4312463852 hasConceptScore W4312463852C2776983459 @default.
• W4312463852 hasConceptScore W4312463852C2778715236 @default.
• W4312463852 hasConceptScore W4312463852C2779134260 @default.
• W4312463852 hasConceptScore W4312463852C2779496540 @default.
• W4312463852 hasConceptScore W4312463852C2908647359 @default.
• W4312463852 hasConceptScore W4312463852C3008058167 @default.
• W4312463852 hasConceptScore W4312463852C3013748606 @default.
• W4312463852 hasConceptScore W4312463852C512399662 @default.
• W4312463852 hasConceptScore W4312463852C524204448 @default.
• W4312463852 hasConceptScore W4312463852C71924100 @default.
• W4312463852 hasConceptScore W4312463852C89623803 @default.
• W4312463852 hasConceptScore W4312463852C99454951 @default.
• W4312463852 hasLocation W43124638521 @default.
• W4312463852 hasOpenAccess W4312463852 @default.
• W4312463852 hasPrimaryLocation W43124638521 @default.
• W4312463852 hasRelatedWork W2007692022 @default.
• W4312463852 hasRelatedWork W2546668150 @default.
• W4312463852 hasRelatedWork W2605835179 @default.
• W4312463852 hasRelatedWork W2742277444 @default.
• W4312463852 hasRelatedWork W2809872158 @default.
• W4312463852 hasRelatedWork W2996474769 @default.
• W4312463852 hasRelatedWork W3007495149 @default.
• W4312463852 hasRelatedWork W3040466112 @default.
• W4312463852 hasRelatedWork W3080106733 @default.
• W4312463852 hasRelatedWork W3122948194 @default.
• W4312463852 isParatext "false" @default.
• W4312463852 isRetracted "false" @default.
• W4312463852 workType "article" @default.